Trial Condition(s):

Wet Macular Degeneration

The impact of baseline visual acuity on the treatment outcomes in patients treated with AflIbercept in real-life clinical setting (INSIGHT)

Bayer Identifier:

19473

ClinicalTrials.gov Identifier:

NCT03278262

EudraCT Number:

Not Available

Study Completed

Trial Purpose

The study will assess the mean change in Visual Acuity (VA) (overall and stratified by baseline VA) at year 1 and 2 of treatment with Aflibercept in real-life setting.
In addition, the study will ascertain the baseline VA in treatment –naïve Wet Age-Related Macular Degeneration or neo-vascular AMD (wAMD) patients who start treatment with Aflibercept in a real-life setting and it will assess the impact of baseline VA on the outcomes of Aflibercept treatment.

Inclusion Criteria
-Treatment-naïve eyes with neovascularization AMD, with the indication to be treated with Aflibercept. One and/or two eyes per patient.
Exclusion Criteria
-Eyes treated previously with another anti-VEGF drug.

Trial Summary

Enrollment Goal
2312
Trial Dates
black-arrow
Phase
N/A
Could I receive a placebo?
No
Products
Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)
Accepts Healthy Volunteers
No

Where to Participate

Loading...
Locations
Status
LocationsStatus
Locations

Many locations

Lund, Sweden

Status
Completed
 

Trial Design